Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma - subgroup analysis of the PEVOsq basket trial

被引：0
|
作者：
Le Tourneau, C. [1 ]
Ghiringhelli, F. [2 ]
Saada, E. B. [3 ]
Chaltiel, R. [4 ]
Vansteene, D. [5 ]
Durando, X. [6 ]
You, B. [7 ]
Borel, C. [8 ]
Bigot, F. [9 ]
Abdeddaim, C. [10 ]
Marret, G. [11 ]
Jeannot, E. [12 ]
Rocco, E. Guerini [13 ]
Frige, G. [14 ]
Servant, N. [15 ]
Dupain, C. [16 ]
Kamal, M. [16 ]
Legrand, F. [17 ]
Jimenez, M. [17 ]
Filleron, T. [18 ]
机构：
[1] Inst Curie, Dept Drug Dev & Innovat D3i, Paris, France
[2] Ctr Georges Francois Leclerc Dijon, Med Oncol, Dijon, France
[3] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France
[4] CHU Reims, Hop Robert Debre, Reims, France
[5] ICO Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France
[6] Ctr Jean PERRIN, F-63000 Clermont Ferrand, France
[7] HCL, Ctr Hosp Lyon Sud, Oncol Dept, Pierre Benite, France
[8] Ctr Lutte Canc, Ctr Paul Strauss, Med Oncol Dept, Strasbourg, France
[9] ICO Inst Cancerol Ouest, Dept Med Oncol, Site Paul Papin, Angers, France
[10] Ctr Oscar Lambret, Dept Med Oncol, Lille, France
[11] Inst Curie, Dept Drug Dev & Innovat, Paris, France
[12] Inst Curie, Pathol, Paris, France
[13] IEO Ist Europeo Oncol IRCCS, Dept Med Oncol, Milan, Italy
[14] IEO Ist Europeo Oncol, Expt Oncol, Milan, Italy
[15] Inst Curie, Dept Med Oncol, Paris, France
[16] Inst Curie, Drug Dev & Innovat Dept, Paris, France
[17] UNICANCER, R&D Dept, Paris, France
[18] IUCT Oncopole, Inst Claudius Regaud, Haute Garonne, Toulouse, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
923P
引用
收藏
页码：S583 / S583
页数：1
相关论文
共 50 条
  • [21] Biomarkers of response and progression to Pembrolizumab and Vorinostat combination in late-stage squamous cell carcinoma patients of different locations included in the PEVOsq basket trial
    Le Tourneau, Christophe
    Mazzarella, Luca
    Cabarrou, Bastien
    Francisco, Miguel
    Dupain, Celia
    Halladjian, Maral
    Frige, Gianmaria
    Duso, Bruno
    Zhan, Yinxiu
    Guerini-Rocco, Elena
    Noberini, Roberta
    Bonaldi, Tiziana
    Tonini, Maria Manuela
    Marret, Gregoire
    Coutzac, Clelia
    Coquan, Elodie
    Saint-Ghislain, Mathilde
    Le Saux, Olivia
    Chanas, Laetitia
    Legrand, Francois
    Filippini, Daria Maria
    Jeannot, Emmanuelle
    Bernhart, Stephan
    Balogh, Gabor
    Jimenez, Marta
    Filleron, Thomas
    Servant, Nicolas
    Kamal, Maud
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Gilbert, Jill
    Cmelak, Anthony
    Shyr, Yu
    Netterville, James
    Burkey, Brian B.
    Sinard, Robert J.
    Yarbrough, Wendall G.
    Chung, Christine H.
    Aulino, Joseph M.
    Murphy, Barbara A.
    CANCER, 2008, 113 (01) : 186 - 192
  • [23] Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Cohen, EEW
    Kane, MA
    List, MA
    Brockstein, BE
    Mehrotra, B
    Huo, DZ
    Mauer, AM
    Pierce, C
    Dekker, A
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2005, 11 (23) : 8418 - 8424
  • [24] Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).
    Rodriguez, Cristina P.
    Wu, Vicky
    Voutsinas, Jenna M.
    Fromm, Jonathan P.
    Pillarisetty, Venu Gopal
    Lee, Sylvia
    Santana-Davila, Rafael
    Goulart, Bernardo H. L.
    Baik, Christina S.
    Chow, Laura Quan Man
    Eaton, Keith D.
    Martins, Renato G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Varadarajan, Prakash
    Kotsakis, Athanasios Panayotis
    Martin, Daniel
    Gutkind, Jorge Silvio
    Gibson, Michael K.
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Kim, Hana
    Park, Sehhoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Park, Keunchil
    Ahn, Yong Chan
    Oh, Dongryul
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1104 - 1112
  • [27] A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial
    Williamson, S. K.
    Moon, J.
    Huang, C. H.
    Guaglianone, P.
    Wolf, G. T.
    Urba, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    Argiris, A.
    Kotsakis, A. P.
    Hoang, T.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Gyanchandani, R.
    Blumenschein, G. R., Jr.
    Chen, H. X.
    Grandis, J. R.
    Harari, P. M.
    Kies, M. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 220 - 225
  • [29] Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck (RMHNC).
    Ikpeazu, CV
    Murphy, BA
    Kish, B
    Cmelak, A
    Shyr, Y
    Netterville, J
    Burkey, B
    Chung, C
    Yarbrough, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 508S - 508S
  • [30] Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
    Massarelli, Erminia
    Ginsberg, Lawrence E.
    Lin, Heather
    Tran, Hai T.
    Lee, J. Jack
    Williams, Michelle D.
    Blumenschein, George R.
    Lu, Charles
    Kies, Merrill S.
    Papadimitrakopoulou, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345